DAFTAR PUSTAKA

Ackerman, B.H., Guilday, R.E., Reigart, C.L., Patton, M.L. & Haith, L.R. 2013.
Evaluation of the relathionship between elevated vancomycin trough
concentrations and increased efficacy and/or toxicity. J. Burn. Care. Res. 34: 1-
9.
Akil, I.O., Mir, S. 2001. Hemodiafiltration for vancomycin overdose in a patient with
end-stage renal failure. Pediatr. Nephrol. 16: 1019-1021.
An, S.Y., Hwang, E.K., Kim, J.H., Kim, J.E., Jin, H.J., Jin, S.M., Kyun, J.O., Lee, Y.H.,
Park, H.S., Choi, Y.W., Lim, S.K. & Ye, Y.M. 2011. Vancomycin-associated
spontaneous cutaneous adverse drug reactions. Allergy Asthma Imunol.Res. 3(3):
194-198.
Ashley, C. & Currie, A. 2009. The Renal Drug Handbook, 3th Edition, New York:
Radcliffe Publishing Oxford
Balen, R.M., Betts, T. & Ensom, M.H.H. 2000. Vancomycin overdose in a 6-month-
old girl. CHJP. 53(1): 32-35.
Bauer, L.A. 2006. Clinical Pharmacokinetics Handbook. New York: McGraw-Hill
Companies.
Bauer, L.A. 2008. Applied Clinical Pharmacokinetics. 2nd Ed. New York: The Graw-
Hill Companies.
Baxter, K. 2010. Stockley’s Drug Interactions A Source Book of Interactions Their
Mechanism Clinical Importance and Management Drug Interactions. Ninth
Edition, London: Pharmaceutical Press.
Bayer, A.S. & Murray, B.E. 2009. Initial low-dose aminoglycosides in Staphylococcus
aureus bacteremia: good science, urband legend, or just plain toxic? Clin. Infect.
Dis. 48: 713-721.
Bosso, J.A., Nappi, J., Rudisill, C., Wellein, M., Bookstaver, P.B., Swindler, J. &
Mauldin, P.D. 2011. Relationship between Vancomycin Trough Concentrations
and Nephrotoxicity: a Prospective Multicenter Trial. Antimicrob. Agents
Chemother. 55: 5475-5479.
Brown, D.L., Lalla, C.D. and Masselink, A.J. 2013. AUC versus Peak-Trough Dosing
of Vancomycin: Applying New Pharmacokinetic Paradigms to an Old Drug.
Ther. Drug. Monit. 35: 443-449.
Butranova, O.I. & Razdrogina, T.N. 2015. Antibiotics for skin and soft tissues
infections in type 2 diabetes mellitus. Int. J. Risk. Saf. Med. Suppl 1:S57-S58.

88
Callum, L.M. 2014. Optimal Medication Dosing in Patients with Diabetes Mellitus and
Chronic Kidney Disease, Can. J. Diabetes. 38(5): 334-343.
Cecilia, C. & Maramba-Lazarte, M.D. 2010. Determining correct dosing regimens of
antibiotics based on the their bactericidal activity. PIDSP Journal. 11(2): 44-49
Craig, C.R., & Stitzel, R.E. 2007. Modern Pharmacology with Clinical Application.
New York: The McGraw-Hill Companies.
Crew, P., Heintz, S.J. & Heintz, B.H. 2015. Vancomycin dosing and monitoring for
patients with end-stage renal disease receiving intermittent hemodialysis. Am. J.
Health-Syst Pharm. 72(1): 1856-1864.
Departemen Kesehatan Republik Indonesia. 1995. Farmakope Indonesia Edisi IV.
Jakarta: Direktorat Jenderal Pengawasan Obat dan Makanan.
Departemen Kesehatan. 2011. Peraturan Menteri Kesehatan Republik Indonesia
Nomor 2406/Menkes/Per/XII/2011 tentang Pedoman Umum Penggunaan
Antibiotik. Jakarta: Kementrian Kesehatan Republik Indonesia.
Departemen Kesehatan Republik Indonesia. 2015. Keputusan Menteri Kesehatan
Republik Indonesia Nomor HK. 02.02/Menkes/523/2015 tentang Formularium
Nasional. Jakarta: Kementrian Kesehatan Republik Indonesia.
Doogue, M.P. & Polasek, T.M. 2011. Drug Dosing in Renal Disease. Clin. Biochem.
Rev. 32(2): 69-73.
Elyasi, S., Khalili, H., Dashti-Khavidaki, S. & Mohammadpour, A. 2012. Vancomycin-
induced nephrotoxicity: mechanism, incidence, risk factor and special
populations. A literature review. Eur.J. Clin. Pharmacol. 68(9): 1243-1255.
Escobar, L., Andresen, M., Downey, P., Gai, M.N., Regueira, T., Borquez, T., Lipman,
J. & Roberts, J.A. 2014. Population pharmacokinetics and dose simulation of
vancomycin in critically ill patients during high-volume haemofiltration. Int. J.
Antimicrob. Agents. 44(2): 163-167.
Giusti, D.L. & Hayton, W.L. 1973. Dosage regimen adjustment in renal impairment.
Drug Intell. Clin. Pharm. 7: 382-387.
Goodman & Gilman. 2006. The Pharmacological Basis of Therapeutics. 11th Ed. New
York: The Mc. Graw-Hill Companies.
Goodman & Gilman. 2007. Dasar Farmakologi Terapi. Edisi 10. Jakarta: EGC.

Gray, A., Wright, J., Goodey, V. & Bruce, L., 2011. Injectable Dugs Guide. London:
Pharmaceutical Press.

89
Green, B.N., Johnson, C.D., Egan, J.T., Rosenthal, M., Griffith, E.A., Evans, M.W.
2012. Methicillin-resistant Staphylococcus aureus: an overview for manual
therapists. J. Chiropr. Med. 11(1): 64-76.
Gritter, R.J., Bobbit, J.M., & Schwarting, A.E. 1991. Pengantar Kromatografi. (Edisi
kedua ). Penerjemah: Kosasih Padmawinata. Bandung: Penerbit ITB.
Gunawan, G.S. 2009. Farmakologi dan Terapan. Edisi 5. Jakarta: Departemen
Farmakologi dan Terapeutik Fakultas Kedokteran Universitas Indonesia.
Gupta, A., Biyani, M. & Khaira, A. 2011. Vancomycin nephrotoxicity: myths and facts.
Neth. J. Med., 69(9):379-383.
Hanrahan, T., Whitehouse T., Lipman, J. & Roberts, J.A. 2015. Vancomycin-
associated nephrotoxicity: A meta-analysis of administration by continuous
versus intermittent infusion. Int. J. Antimicrob. Agents. 46(3): 249-253.
Hashizume, H., Takahashi, Y., Harada, S. & Nomoto, A. 2015. Natural lipopeptide
antibiotic tripropeptin C revitalizes and synergistically potentiates the activity of
beta-lactams against methicillin-resistant Stapylococcus aureus. J. Antibiot. 68:
373-378.
Hassan, Y., Al-Ramahi, R.J., Aziz, N.A. & Ghazali, R. 2009. Impact of a Renal Drug
Dosing Service on Dose Adjustment in Hospitalized Patients with Chronic
Kidney Disease. Ann. Pharmacother. 43: 1598-1605.
Hazlewood, K.A., Brouse, S.D., Pitcher, W.D. & Hall, R.G. 2010. Vancomycin-
Associated Nephrotoxicity: Grave Concern or Death by Character
Assassination? Am. J. Med. 123(2): 1-11.
Hernandez, A.L., & Johnson, C.E. 1982. Estimation of creatinine clearance in children:
comparison of six methods. Clin Pharm. 1(2): 158-161.
Hong, L.T., Goolsby, T.A., Sherman, D.S., Mueller, S.W., Reynolds, P., Cava, L.,
Neumann, R. & Kiser, T.H. 2015. Continuous infusion vs intermittent
vancomycin in neurosurgical intensive care unit patients. J.Crit. Care. 30, 1-6.
Humbert, G., Spyker, D.A., Fillastre, J.P. & Leroy, A. 1979. Pharmacokinetics of
Amoxicillin: Dosage Nomogram for Patients with Impaired Renal Function.
Antimicrob. Agents Chemother. 15(1): 28-33.
Humphreys, H., Fitzpatick, F. & Harvey, B.J. 2015. Gender differences in rates of
carriage and bloodstream infection caused by methicillin-resistant
Staphylococcus aureus: are they real, do they matter and why? Clin. Infect. Dis.
61(11): 1708-1714.
Ippolito, G., Leone, S., Lauria, F.N., Nicastri, E. & Wenzel, R.P. 2010. Methicillin-
resistant Staphylococcus aureus: the superbug. Int. J. Infect. Dis. 14(Suppl 4): 7-
11.

90
Janknegt, R. 1990. Pharmacokinetics of antimicrobial agents in organ function
impairment. Int. J. Clin Pharm. 12(4): 121-127.
Karsono, B. 2006. Ilmu Penyakit Dalam, volume II. Jakarta: Pusat Penerbitan
Departemen IPD FKUI.
Katzung, B.G. 2012. Basic & Clinical Pharmacology. 12th Ed. New York: The Mc
Graw-Hill Companies.
Khudaibergenova, M.S. 2015. Antimicrobial use at a multi-disciplinary hospital. Int. J.
Risk. Saf. Med. Suppl 1: S13-S14.
Kilbre, H.S., Stevens, P.E., Eaglestone, G., Knight, S., Carter, J.L., Delaney, M.P.,
Farmer, C.K., Irving, J., O’Riordan, S.E., Dalton, R.N. & Lamb, E.J. 2013.
Accuracy of the MDRD (Modification of Diet in Renal Disease) study and CKD-
EPI (CKD Epidemiology Collaboration) equations for estimation of GFR in the
elderly. Am.J. Kidney Dis. 61(1): 57-66.
Klevens, R.M., Morrison, M.A., Nadle, J., Petit, S., Gershman, K. & Ray, S. 2007.
Invasive methicillin-resistant Stapylococcus aureus infections in the United
States. JAMA. 298(15): 1763-1771.
Krol, G.D. 2011.Chronic Kidney Disease (CKD) Clinical Practice Recommendations
for Primary Care Physicians and Healthcare Providers. Divisons of Nephrology
& Hypertension and General Internal Medicine Henry Ford Health System.
Lacy, C. F., 2013, Drug Information Handbook 22nd edition, American Pharmacists
Association, Lexi-Comp.
Le, J. Capparelli, E.V., Wahid, U., Shuan, Y., Romanowski, G.L., Tran, T.M., Nguyen,
A. & Bradley, J.S. 2015. Bayesian Estimation of Vancomycin Pharmacokinetics
in Obese Children: Matched Case-Control Study. Clin. Ther. 37(6): 1340-1351.
Lepist, E.I. & Ray, A.S. Renal drug-drug interactions: what we have learned and where
we are going. Expert. Opin. Drug. Metab. Toxicol. 8(4): 433-448.
Levey, A.S., Bosch, J.P., Lewis, J.B., Greene, T., Rogers, N. & Roth, D. 1999. A more
accurate method to estimate glomerular filtration rate from serum creatinine: a
new prediction equation. Modification of Diet in Renal Disease Study Group.
Ann. Intern. Med. 130(6): 461-470.
Levey, A.S. & Coresh, J. 2002. National Kidney Foundation. K/DOQI Clinical Practice
Guidelines for Chronic Kidney Disease: Evaluation, Classification and
Stratification. Am. J. Kidney. Dis. 39: S1-S266
Levey, A.S., Stevens, L.A., Schmid, C.H., Zhang, Castro, A.F., Feldman, H.I., Kusek,
J.W., Eggers, P., Van Lente, F., Greene, T. & Coresh, J. 2009. A New Equation
to Estimate Glomerular Filtration Rate. Ann. Intern. Med. 150: 604-612.
Liu, C., Bayer, A., Cosgrove, S.E., Daum, R.S., Fridkin, S.K., Gorwitz, R.J., Kaplan,
S.L., Karchmer, A.W., Levine, D.P., Murray, B.E., Rybak, M.J., Talan, D.A. &

91
 Chambers, H.F. 2011. Clinical practice guidelines by the Infectious Diseases
Society of America for the treatment of methicillin-resistant Staphylococcus
aureus infections in adults and children: executive summary. Clin. Infect. Dis.
52(3): 285-292.
Lullman, H., Mohr, K., Ziegler, A., & Bieger, D. 2000. Color Atlas of Pharmacology.
New York: Thieme.
Matzke, G.R., McGory, R.W., Halstenson, C.E. and Keane, W.F. 1984.
Pharmacokinetics of vancomycin in patients with various degrees of renal
function. Antimicrob. Agents Chemother. 25: 433-437.
Matzke, G.R., & Frye, R.F. 1997. Drug administration in patients with renal
insufficiency: minimizing renal and external toxicity. Drug Safety. 16: 205-231.
McEvoy, G.K. 2011. AHFS Drug Information. Bethesda, Maryland: American Society
of Health-System Pharmacists®
McKinnon, P.S. & Yu, V.L. 2004. Pharmacologic Considerations in Antimicrobial
Therapy, with Emphasis on Pharmacokinetics and Pharmacodynamics:
Reviews for the Practicing Clinician. Eur. J. Clin. Microbiol. Infect. Dis. 23:
231-232.
Michels, W.M., Grootendorst, D.C., Verduijn, M., Elliot, E.G., Dekker, F.W. &
Krediet, R.T. 2010. Performance of the Cockcroft-Gault, MDRD and new
CKD-EPI formulas in relation to GFR, age, and body size. Clin J. Am. Soc.
Nephrol. 5: 1003-1009.
Moellering, R.C., Krogstad, D.J. & Greenblatt, D.J. 1981. Vancomycin therapy in
patients with impaired renal function: a nomogram for dosage. Ann. Intern.
Med. 94: 343-346.
Myrna, Y., Munar & Harleen. 2007. Drug Dosing Adjustments in Patients with Chronic
Kidney Disease. Am. Fam. Physician. 75(10): 1487-1496.
Obach, R.S., Lombardo, F. & Waters, N.J. 2008. Trend analysis of a database of
intravenous pharmacokinetic parameters in human for 670 drug compounds.
Drug Metab. Dispos. 36(7): 1385-1405.
Owens, R.C. & Shorr, A.F. 2009. Rational dosing of antimicrobial agents:
pharmacokinetic and pharmacodynamics strategies. Am. J. Health. Syst. Pharm.
66: S23-30.
Palylyk-Colwell, E., Jamali, F., Dryen, W., Friesen, E., Koven, S., Mohamed, I.,
Osmond, B., Alessi-Severini, S., Sheldon, L., Sheldon, R., Tam, Y., Tsuyuki, R.,
& Zhanel, G. 1998. Bioequivalence and interchangeability of narrow therapeutic
range drugs. J. Pharm. Pharm. Sci. 1(1), 2-7.

92
Pai, M.P., Neely, M., Rodvold, K.A. & Lodise, T.P. 2014. Innovative approaches to
optimizing the delivery of vancomycin in individual patients. Adv. Drug Deliv.
Rev. 77: 50-57.
Panwar, B., Johnson, V.A., Patel, M. & Balkovetz, D.F. 2013. Risk of vancomycin-
induced nephrotoxicity in the population with chronic kidney disease. Am J. Med.
Sci. 345: 396-399.
Parfati, N., Budisutio, F. H. & Tan, C. K. 2004. Farmakokinetika Klinis dalam Farmasi
Klinis-Menuju Pengobatan Rasional dan Penghargaan Pilihan Pasien, Editor
Aslam, Moh, Chik Kaw Tan, Adji Prayitno. Jakarta: PT. Alex Media
Komputindo.
Patel, K., Crumby, A.S. & Maples, H.D. 2015. Balancing Vancomycin Efficacy and
Nephrotoxicity: Should We Be Aiming for Trough or AUC/MIC. Pediatr. Drugs.
17(2): 97-103.
Purwonugroho, T.A., Chulavatnatol, S., Preechagoon, Y., Chindavijak, B., Malathum,
K., and Bunuparadah, P. Population Pharmacokinetics of Vancomycin in Thai
Patients. Sci. World J. 2012: 1-8.
Rice, P.J., Perry, R.J., Afzal, Z. & Stockley, I.H. 2003. Antibacterial prescribing and
warfarin: a review. Br. Dent. J., 194(8): 411-415.
Riviere, J.E. 2011. Comparative Pharmacokinetics: Principles, Techniques, and
Applications. Second Edition, John Wiley & Sons, Inc.
Rowland, H. and Tozer, T.N. 1980. Clinical Pharmacokinetics, Concept and
Applications. Philadelphia: Lea & Febiger.
Rubinstein, E., Keynan, Y. 2014. Vancomycin revisited-60 years later. Front Public
Health. 31(2):217.
Rule, A.D., Bailey, K.R., Schwartz, G.L., Khosla, S., Lieske, J.C., Melton, L.J.3rd.
2009. For estimating creatinine clearance measuring muscle mass gives better
result than those based on demographics. Kidney Int. 75(10):1071-1078.
Rybak, M.J. 2006. The Pharmacokinetic and Pharmacodynamic Properties of
Vancomycin. CID. 42: S35-S39.
a
Rybak, M., Lomaestro, B., Rotschafer, J.C., Moellering, Jr.R., Craig, W. & Billeter,
M. 2009. Therapeutic monitoring of vancomycin in adult patients: a consensus
review of the American Society of Health-System Pharmacist, the Infectious
Diseases Society of America, and the Society of Infectious Diseases Society of
America, and the Society of Infectious Diseases Pharmacists. Am. J. Health.
Syst.Pharm. 66: 82-98.
b
Rybak, M., Lomaestro, B., Rotschafer, J.C., Moellering, Jr.R., Craig, W., Billeter, M.,
Dalovisio, J.R. & Levine, D.P. 2009. Vancomycin Therapeutic Guidelines: A

93
 Summary of Consensus Recommendations from the Infectious Diseases Society
of America, the American Society of Health-System Pharmacists, and the Society
of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49: 325-327.
Salazar, D.E., & Corcoran, G.B. 1988. Predicting creatinine clearance and renal drug
clearance in obese patients from estimated fat-free body mass. Am. J. Med. 84(6):
1053-1060.
Schwartz, A., Brion, L.P., & Spitzer, A. 1987. The use of plasma creatinine
concentration for estimating glomerular filtration rate in infants, children, and
adolescents, Pediatr. Clin. North. Am. 34 (3): 571-590.
Smith, D.A., Jones, B.C and Walker, D.K. 1996. Design of Drugs Involving the
Concepts and Theories of Drug Metabolism and Pharmacokinetics. Med. Res.
Rev. 16(3): 243-266.
Sennang, N., Sulina, Badji, A., Hardjoeno. 2005. Laju Filtrasi Glomerulus Pada Orang
Dewasa Berdasarkan Tes Klirens Kreatinin Menggunakan Persamaan Cockroft-
Gault dan Modification of Diet in Renal Disease. J. Med. Nus. 24(2): 80-84.
Shargel, L., Wu-Pong, S., & Yu,A.B. 2005. Applied Biopharmaceutics and
Pharmacokinetics. 5th Ed. New York: The Mc Graw-Hill Companies.
Siau, K. 2009. Hypokalaemia and cardiac arrest complicating vancomycin and
furosemide therapy : a case report. Cases J. 2 : 8244.
Sihombing, J.P., Hakim, L., Kusharwanti, W. 2011. Evaluasi Dosis Digoksin Pada
Pasien Gagal Jantung dengan Disfungsi Ginjal di RSUP Dr. Sardjito,
Yogyakarta. Journal of Management and Pharmacy Practice (JMPF). 1(3).
Siregar, C.J.P. & Endang, K. 2006. Farmasi Klinik Teori dan Terapan. Jakarta, EGC.

Smith, K.M., Riche, D.M. & Henyan, N.N. 2010. Clinical Drug Data. New York: The
Mc Graw-Hill Companies.
Song, K.H., Kim, H.B., Kim, H.S., Lee, M.J., Jung, Y., Kim, G., Hwang, J.H., Kim,
N.H., Kim, M., Kim, C.J., Choe, Pyoeng Gyun, Chung, J.Y., Park, W.B., Kim,
E.S., Park, W.B., Kim, E.S., Park, K.U., Kim, N.J., Kim, E.C. & Oh, M.D. 2015.
Impact of area under the concentration-time curve to minimum inhibitory
concentration ratio on vancomycin treatment outcomes in methicillin-resistant
Staphylococcus aureus bacteraemia. Int. J. Antimicrob. Agents. 10(15): 331-333.
Stengel, B. 2010. Chronic kidney disease and cancer: a troubling connection. J.
Nephrol. 23(3): 253-263.
Stepensky, D. 2013. Prediction of drug disposition on the basis of its chemical
structure. Clin, Pharmacokinet. 52(6): 415-431.

94
Sweetman, S.C. 2009. Martindale : The Complete Drug Reference, 36th Edition,
Pharmaceutical Press London.
Tandi, M., Mongan, A. & Manopo, F., 2014. Hubungan Antara Derajat Penyakit Ginjal
Kronik Dengan Nilai Agregasi Trombosit di RSUP Prof. Dr. D. Kandou Manado.
J. eBM. 2(2): 509-513.
Taylor, M.E. & Allon, M. 2010. Practical Vancomycin Dosing in Hemodialysis Patients
in the Era of Emerging Vancomycin Resistance: A Single-Center Experience. Am.
J. Kidney Dis. 55(6): 1163-1165.
Tiong, H.Y., Huang, P., Xiong, S., Li, Y., Vathsala, A. & Zink, D. 2014. Drug-Induced
Nephrotoxicity: Clinical Impact and Preclinical in Vitro Models. Mol.
Pharmaceutics. 11(7): 1933-1948.
Traub, S.L., & Johnson, C.E. 1980. Comparison of method of estimating creatinine
clearance in children. Am.J. of Hosp. Pharm. 37: 195-201.
Trissel, 2011, Handbook on Injectable Drugs, 16th Edition. Bethesda, Maryland:
American Society of Hospital Pharmacists, Inc.
UK Health Departements. 2009. British National Formulary 57. London: BMJ Group
& RPS Publishing.
Urso, R., Blardi, P. & Giorgi, G. 2002. A short introduction to pharmacokinetics. Eur.
Rev. Med. Pharmacol. Sci. 6: 33-44.
Vacher, V.L., Izzedine, H., Mercadal, L. & Deray, G. 2002. Clinical review: Use of
vancomycin in haemodialysis patients. J. Crit. Care. 6: 313-316.
Valente, M.A., Hillege, H.L., Navis, G., Voors, A.A., Dunselman, P.H., van
Veldhuisen, D.J. & Damman, K. 2014. The Chronic Kidney Disease
Epidemiology Collaboration equation outperforms the Modification of Diet in
Renal Disease equation for estimating glomerular filtration rate in chronic
systolic heart failure. Eur. J. Heart. Fail. 16(1): 86-94.
van Hal, S.J., Paterson, D.L. & Lodise, T.P. 2013. Systematic Review and Meta-
Analysis of Vancomycin-Induced Nephrotoxicity Associated with Dosing
Schedules That Maintain Troughs between 15 and 20 Milligrams per Liter.
Antimicrob. Agents and Chemother. 57(2): 734-744.
Vandecasteele, S.J & De Vriese, A.S. 2010. Recent changes in vancomycin use in renal
failure. Kidney Int. 77: 760-764.
Vandecasteele, S.J & De Vriese, A.S. 2011. Vancomycin Dosing in Patients on
Intermittent Hemodialysis. Seminar in Dialysis. 24(1): 50-55.
Vandecasteele, S.J., De Vriese, A.S. & Tacconelli, E. 2013. The Pharmacokinetics and
pharmacodynamics of vancomycin in clinical practice: evidence and
uncertainties. J. Antimicrob. Chemother. 68: 743-748.

95
Wagner, J. & Nelson, E. 1964. Wagner-Nelson Method. J. Pharm. Sci. 53: 1392.
Wells, B.G., DiPiro, J.T., Schwinghammer, T.L. & DiPiro, C.V. 2015.
Pharmacotherapy Handbook. New York: McGraw-Hill.
Ye, Z.K., Tang, H.L. & Zhai, S.D. 2013. Benefits of Therapeutic Drug Monitoring of
Vancomycin: A Systematic Review and Meta-Analysis. PLoS. 8(10): 1-10
Yulianti, T., Hakim, L. & Putranto, W. 2007. Evaluasi Penggunaan Antibiotik pada
Pasien Penyakit Ginjal Kronik Rawat Inap di RSUP Dr. Moewardi Surakarta
Periode September – November 2007 (Tesis). Yogyakarta: UGM
Zorgani, A.A., Elahmer, O., Abaid, A., Elaref, A., Elamri, S., Aghila, E. & Tubbal, A.
2015. Vancomycin susceptibility trends of methicillin-resistant Staphylococcus
aureus isolated from burn wounds: a time for action. J. Infect. Dev. Ctries. 9(11):
1284-1288.

96